ICMR, SII complete enrolment of Phase III clinical trials of COVISHIELD vaccine
A view of the production facilities at the Serum Institute of India, PuneFile photo (Serum Institute)

ICMR, SII complete enrolment of Phase III clinical trials of COVISHIELD vaccine

New Delhi, November 12, 2020

Serum Institute of India (SII), the largest vaccine manufacturer in the world by volume, and Indian Council of Medical Research (ICMR), the apex body in India for biomedical research, today announced completion of enrolment of phase 3 clinical trials for the COVISHIELD vaccine against COVID-19 in India.

ICMR and SII have further collaborated for clinical development COVOVAX (Novavax) developed by Novavax, USA and upscaled by SII.

"The partnership is a stellar example of private-public institutes collaborating to mitigate the dire consequences of the pandemic outbreak," a press release from ICMR said here.

ICMR has funded the clinical trial site fees while SII has funded other expenses for COVISHIELD. At present, SII and ICMR are conducting Phase 2/3 clinical trial of COVISHIELD at 15 different centres, across the country. It has completed the enrolment of all 1,600 participants on October 31.

COVISHIELD has been developed at the SII Pune laboratory with a master seed from Oxford University/Astra Zeneca. The vaccine made in the UK is currently being tested in large efficacy trials in UK, Brazil, South Africa and USA.

"The promising results of the trials so far give confidence that COVISHIELD could be a realistic solution to the deadly pandemic," the release said.

According to it, COVISHIELD is by far the most advanced vaccine in human testing in India. Based on the Phase 2/3 trial results, SII with the help of ICMR will pursue the early availability of this product for India. SII has already manufactured 40 million doses of the vaccine, under the at-risk manufacturing and stockpiling license from DCGI.

Furthermore, US-based Novavax has initiated its late phase trials in South Africa and in UK and will soon commence the same in the USA. SII has received the bulk vaccine and Matrix-M adjuvant from Novavax and will soon fill and finish them in vials.

This vaccine formulated at SII (COVOVAX) will be tested in a Phase 3 trial in India and an application for the same to regulatory authorities will be made soon by ICMR and SII.

Commenting on the association, Adar Poonawalla, CEO of Serum Institute of India, said, “ICMR has played a huge role in coming forward and strengthening India’s fight against COVID-19. The collaboration will further aid us in putting India at the forefront of developing an immunogenic and efficacious vaccine. The pandemic has presented a chance to foster structural reforms in building robust public healthcare infrastructure. The partnership further testifies the importance of private-public institutes coming together in scaling up the management and containing the spread of the virus.”

Dr. Balram Bhargava, Director General of Indian Council of Medical Research (ICMR), said, “At present, India plays a prominent role in vaccine development and manufacturing globally. Buoyed by the latest technology and well-equipped facilities, SII has continually proven its research and manufacturing prowess. The partnership is our contribution to lending our expertise and support to bolster our fight against the global pandemic.”

The partnership will see the scientists of both the entities facilitate the advancement of regulatory approvals for COVISHIELD and COVOVAX while ensuring strict adherence to all the requisite scientific, ethical and regulatory standards.

NNN

Related Stories

NetIndian
www.netindian.in